NGF and neoplasm: A pertinent example of this strategy is the application of NGF-targeting monoclonal antibodies, such as tanezumab, which are currently undergoing Phase III clinical trials for the treatment of painful bone metastases, potentially providing the dual advantages of alleviating pain while controlling tumor growth.